The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study

阿帕蒂尼 医学 肝细胞癌 内科学 联合疗法 胃肠病学 不利影响 肿瘤科 酪氨酸激酶抑制剂 实体瘤疗效评价标准 肝癌 无进展生存期 癌症 化疗 临床研究阶段
作者
Zeran Yang,Guang Chen,Ye Cui,Xiao Guo-wen,Ting Su,Jianan Yu,Zhiyuan Zhang,Yanjing Han,Kai-Lan Yang,Long Jin
出处
期刊:Cancer Biology & Therapy [Informa]
卷期号:20 (3): 321-327 被引量:34
标识
DOI:10.1080/15384047.2018.1529099
摘要

As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
有机小鸟发布了新的文献求助10
1秒前
细腻的山水完成签到,获得积分10
1秒前
高兴翠绿完成签到,获得积分10
2秒前
研友_VZG7GZ应助好好学习采纳,获得10
2秒前
3秒前
科目三应助凶狠的初夏采纳,获得10
3秒前
南北发布了新的文献求助10
3秒前
3秒前
Hello应助8788采纳,获得10
3秒前
可爱的函函应助like1994采纳,获得10
4秒前
Akim应助xiaoleeyu采纳,获得10
4秒前
xiaoman完成签到,获得积分20
5秒前
顶刊收割机完成签到,获得积分10
5秒前
无奈的鹤完成签到,获得积分10
5秒前
5秒前
传奇3应助风中的绿凝采纳,获得10
6秒前
薄幸关注了科研通微信公众号
6秒前
loulex关注了科研通微信公众号
6秒前
小庄同学发布了新的文献求助10
6秒前
蘑菇完成签到,获得积分20
6秒前
bkagyin应助电催化丁真采纳,获得10
6秒前
colorful发布了新的文献求助10
7秒前
Singularity应助Ayla采纳,获得10
7秒前
Guochunbao完成签到,获得积分10
8秒前
lonelymusic完成签到,获得积分10
8秒前
kcul完成签到 ,获得积分10
9秒前
玩命的若发布了新的文献求助10
9秒前
小二郎应助Suu采纳,获得10
10秒前
尊敬的yy完成签到,获得积分10
11秒前
11秒前
uiwh发布了新的文献求助30
11秒前
平常发卡发布了新的文献求助10
12秒前
12秒前
joshar发布了新的文献求助10
12秒前
万能图书馆应助能能采纳,获得10
14秒前
15秒前
小鲸鱼完成签到,获得积分10
16秒前
16秒前
zzz完成签到,获得积分10
17秒前
17秒前
高分求助中
Spray / Wall-interaction Modelling by Dimensionless Data Analysis 2000
Aspects of Babylonian celestial divination: the lunar eclipse tablets of Enūma Anu Enlil 500
Mathematics and Finite Element Discretizations of Incompressible Navier—Stokes Flows 500
Dictionary of socialism 350
Mixed-anion Compounds 300
Geochemistry, 2nd Edition 地球化学经典教科书第二版 300
Idoxuridine 260
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3195624
求助须知:如何正确求助?哪些是违规求助? 2844459
关于积分的说明 8050116
捐赠科研通 2509095
什么是DOI,文献DOI怎么找? 1341427
科研通“疑难数据库(出版商)”最低求助积分说明 639124
邀请新用户注册赠送积分活动 608325